Evidence map›Paper›PMID 41390693›Full record

ArticleNature communications2025

Prodrug nanoplatform for triggering ferroptosis to eliminate senescent cells in age-associated pathologies.

Chengkang Jin, Xiaoling Xu, Ning Yao, Hairui Zhang, Changjiang Chen, Lingyao Zeng, Zhiyun Liu, Lanjie Lei, Shumao Cui, Chengping Wen and 1 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chengkang Jin *Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, Zhejiang, China.ORCID http://orcid.org/0009-0000-9243-0996
Xiaoling Xu *Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, Zhejiang, China. ziyao1988@zju.edu.cn.ORCID http://orcid.org/0000-0002-7472-0495
Ning YaoDepartment of General Surgery, Joint Support Force 903th Hospital, Hangzhou, China.
Hairui ZhangSchool of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.ORCID http://orcid.org/0009-0006-7566-3169
Changjiang ChenDepartment of Immunology and Medical Microbiology, Nanjing University of Chinese Medicine, Nanjing, China.ORCID http://orcid.org/0009-0009-3708-0626
Lingyao ZengKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, Zhejiang, China.ORCID http://orcid.org/0009-0003-9415-3955
Zhiyun LiuKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, Zhejiang, China.ORCID http://orcid.org/0009-0001-1896-0937
Lanjie LeiKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, Zhejiang, China.ORCID http://orcid.org/0000-0003-1773-1646
Shumao CuiState Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi, Jiangsu, China.
Chengping WenCollege of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China. wengcp@163.com.
Liyun ShiKey Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, Zhejiang, China. sly0202@zjsru.edu.cn.ORCID http://orcid.org/0000-0003-3538-1571

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81991523National Natural Science Foundation of China (National Science Foundation of China) 822770014
6 · The paper itself

Abstract

Accumulation of senescent cells is associated with aging and age-related diseases. However, current clearance therapies targeting senescent cells are often limited by low efficiency, poor specificity, and insufficient penetration. Here we develop a nano-platform composed of a probe (GD) that can be specifically activated by senescent cells, a photosensitizer (Ce6), and a peptide (HK) for targeting ferritin, named HK-PCGC. We show that upon entering senescent cells, GD is activated by high levels of β-galactosidase, releasing fluorescence to excite Ce6. Ce6 then generates reactive oxygen species to eliminate these cells. Additionally, we find that under the guidance of the peptide HK, our system degrades ferritin to trigger ferroptosis, further eliminating senescent cells. Collectively, we demonstrate that HK-PCGC can effectively eliminate senescent cells, reduce the senescence-associated secretory phenotype, and safely improve the physical fitness of aged mice. This study integrates senescent cell responsiveness, laser-free photodynamic therapy, and induction of ferroptosis, offering a potential approach for delaying aging.

Indexed as

AgingCellular SenescenceFerroptosisProdrugsAnimalsbeta-GalactosidaseFerritinsHumansMicePeptidesPhotochemotherapyPhotosensitizing AgentsReactive Oxygen Speciesbeta-GalactosidaseFerritinsPeptidesPhotosensitizing AgentsProdrugsReactive Oxygen Species

Identifiers

PMID41390693
PMCPMC12816653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.